Hedi Ben Brahim

Hedi Ben Brahim was CEO of Transgene from 2021 to 2023. During his tenure, he and his team launched two products in clinic and demonstrated the unique benefits of viral based personalized vaccines in a successful phase 1 program. Prior to that, Hedi was Vice-President, Immunotherapy of Institut Mérieux from 2018 to 2020. In this role, he was the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO). Prior to joining the Institut Mérieux, he was General Manager at a subsidiary of Vallourec, a solutions provider to the energy sector. Hedi began his career in the public sector at the Ministry of the Economy, Action and Public Accounts, then at the Ministry of Social Affairs and Health. He is a graduate of École Polytechnique and École Nationale Supérieure des Mines de Paris.